Lobsor Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Lobsor Pharmaceuticals is a clinical-stage biotech company developing Lecigon, a continuous intestinal gel infusion of levodopa/carbidopa/entacapone for advanced Parkinson's disease. The technology aims to provide stable drug delivery, bypass erratic gastric emptying, and allow for a lower levodopa dose, potentially improving quality of life. Founded by executives with experience from the Duodopa product, the company is a privately held subsidiary of STADA Sweden, positioning it for strategic development and potential commercialization in the neurology space.

NeurologyParkinson's Disease

Technology Platform

Proprietary gel formulation for continuous intestinal infusion, enabling stable delivery of drug combinations (e.g., levodopa/carbidopa/entacapone) to bypass erratic gastric emptying and allow for lower drug doses.

Opportunities

Lecigon addresses a high-unmet need in advanced Parkinson's disease, a growing market due to aging populations.

Its potential for lower levodopa dosing and a more convenient pump system could differentiate it from existing intestinal gel therapy.

Being a STADA subsidiary provides a clear path to commercialization in Europe and beyond.

Risk Factors

As a single-asset company, Lobsor faces high clinical and regulatory risk; failure of Lecigon would be catastrophic.

It must also overcome competition from established device-assisted therapies and demonstrate superior value to gain market share.

Successful launch requires executing a complex device-and-drug commercialization strategy.

Competitive Landscape

Lecigon competes in the advanced PD device-assisted therapy market against AbbVie's Duodopa (levodopa/carbidopa intestinal gel), subcutaneous apomorphine infusion (e.g., Britannia's APO-go, Kyowa Kirin's Dacepton), and deep brain stimulation (DBS) systems. Its primary differentiation is the inclusion of entacapone for potentially lower levodopa dose and improved pharmacokinetics compared to Duodopa.

More companies in Sweden →